Fig. 7

Suppressive effects of the selective 5-HT_2A receptor antagonist EMD 281014 on DOI-induced c-fos expression in different regions at 5 coronal sections in the PFC. Compared to the corresponding vehicle + vehicle pretreated control-mice, administration of DOI (i.e. vehicle + DOI (1 mg/kg, i.p.)) evoked greater numbers of c-fos positive cells in the: (i) FrA, LO, and DLO at the level of − 2.68 mm relative to bregma (a, b); (ii) M1, M2, LO, and AI at the level of − 2.34 mm relative to bregma (c, d); (iii) M1, LO, and AI at the level of − 2.1 mm relative to bregma (e, f); (iv) S1, M1, IL, and AI at the level of − 1.98 mm relative to bregma (g, h) and (v) S1 and M1 at the level of − 1.7 mm relative to bregma (i, j). Pretreatment with the selective 5-HT_2A receptor antagonist EMD 281014 (0.1 mg/kg, i.p.) prevented the DOI-induced c-fos expression in the: (i) FrA, MO, LO, and DLO at the level of − 2.68 mm relative to bregma (a, b); (ii) M1, M2, LO, and AI at the level of − 2.34 mm relative to bregma (c, d); (iii) M1, M2, LO, and AI at the level of − 2.1 mm relative to bregma (e, f); (iv) S1, M1, IL, VO, and AI at the level of − 1.98 mm relative to bregma (g, h); and (v) S1 and M1 at the level of − 1.7 mm relative to bregma (i, j). Treatment with EMD 281014 by itself (i.e. EMD 281014 + vehicle group) did not produce a change in c-fos expression in any of the regions tested when compared to vehicle + vehicle treatment control group. *p < 0.05, **p < 0.01, ***p < 0.001 vs. Vehicle + Vehicle pretreated control-mice. ^#p < 0.05, ^##p < 0.01 ^###p < 0.001 vs. Vehicle + DOI treatment group one-way ANOVA followed by Tukey's test. Data are presented as means ± SEM